Compare Johnson & Johnson (JNJ) vs AT&T Inc. (T) Price & Performance

Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.

The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.

AT&T (T) trades at $21.91, up 0.52% today, with a bullish technical signal and strong fundamentals including a 17.47% net income margin and consistent earnings beats. The stock shows improving cash flow trends, with net cash flow turning positive to $15.12B in 2025. Recent news highlights fiber expansion and competitive threats from Starlink, while analyst consensus leans toward a buy with a $26.18 price target.

The outlook is cautiously optimistic given attractive valuation multiples like a P/E of 7.34 and a 19.95% ROE, but risks include intense telecom competition and debt levels. The stock offers a dividend yield supported by sustainable cash flows, positioning it as a value play with moderate growth potential amid industry headwinds.